Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 17, 2008, Pages 4794-4797

  Scott, David A ^a   Aquila, Brian M ^a   Bebernitz, Geraldine A ^a   Cook, Donald J ^a   Dakin, Les A ^a   Deegan, Tracy L ^a   Hattersley, Maureen M ^a   Ioannidis, Stephanos ^a   Lyne, Paul D ^a   Omer, Charles A ^a   Ye, Minwei ^a   Zheng, XiaoLan ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bisamide; CSF 1R; Kinase inhibitors; Thiazole

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR RECEPTOR; PYRIDYL BISAMIDE DERIVATIVE; THIAZOLYL BISAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; RATS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; THIAZOLES;

EID: 50049098522     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.093     Document Type: Article

References (27)

1. Pixley F.J., and Stanley E.R. Trends Cell Biol. 14 (2004) 628
2. Dai X.-M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., Sylvestre V., and Stanley E.R. Blood 99 (2002) 111
3. Sapi E., and Kacinski B.M. Proc. Soc. Exp. Biol. Med. 220 (1999) 1
4. Lewis C.E., and Pollard J.W. Cancer Res. 66 (2006) 605
5. Bingle I., Brown N.J., and Lewis C.E. J. Pathol. 196 (2002) 254
6. Kacinski B.M. Ann. Med. 27 (1995) 79
7. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., Keast P.K., Brassard J.A., O'Farrell A.M., Cherrington J.M., and Pryer N.K. Clin. Exp. Metastasis 20 (2003) 757
8. Guo J., McCall J.O., Marcotte P.A., and Glasser K.B. Proc. Am. Assoc. Cancer Res. 46 (2005) (Abstract 4568)
9. Pfizer analyst meeting; Pfizer WebSite Nov. 30th, 2006.
10. Myers M.R., Setzer N.N., Spada A.P., Persons P.E., Ly C.Q., Maguire M.P., Zulli A.L., Cheney D.L., Zilberstein A., Johnson S.E., Franks C.F., and Mitchell K.J. Bioorg. Med. Chem. Lett. 7 (1997) 421
11. Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M., Yoneda T., and Isoe T. Mol. Cancer Ther. 5 (2006) 2634
12. Conway J.G., McDonald B., Parham J., Keith B., Rusnak D.W., Shaw E., Jansen M., Lin P., Payne A., Crosby R.M., Johnson J.H., Frick L., Lin M.-H.J., Depee S., Tadepalli S., Votta B., James I., Fuller K., Chambers T.J., Kull F.C., Chamberlain S.D., and Hutchins J.T. Proc. Nat. Acad. Sci. U.S.A. 102 (2005) 16078
13. Smalley Jr. T.L., Chamberlain S.D., Mills W.Y., Musso D.L., Randhawa S.A., Ray J.A., Samano V., and Frick L. Bioorg. Med. Chem. Lett. 17 (2007) 6257
14. Irvine K.M., Burns C.J., Wilks A.F., Su S., Hume D.A., and Sweet M.J. FASEB J. 20 (2006) 1921
15. Patch R.J., Brandt B.M., Asgari D., Baindur N., Chadha N.K., Georgiadis T., Cheung W.S., Petrounia I.P., Donatelli R.R., Chaikin M.A., and Player M.R. Bioorg. Med. Chem. Lett. 17 (2007) 6070
16. Illig C.R., Chen J., Wall M.J., Wilson K.J., Ballentine S.K., Rudolph M.J., DesJarlais R.L., Chen Y., Schubert C., Petrounia I.P., Crysler C.S., Molloy C.J., Chaikin M.A., Manthey C.L., Player M.R., Tomczuk B.E., and Meegalla S.K. Bioorg. Med. Chem. Lett. 18 (2008) 1642
17. Wall M.J., Chen J., Meegalla S.K., Ballentine S.K., Wilson K.J., DesJarlais R.L., Schubert C., Chaikin M.A., Crysler C.S., Petrounia I.P., Donatelli R.R., Yurkow E.J., Boczon L., Mazzulla M., Player M.R., Patch R.J., Manthey C.L., Molloy C.J., Tomczuk B.E., and Illig C.R. Bioorg. Med. Chem. Lett. 18 (2008) 2097
18. Huang H., Hutta D.A., Hu H., DesJarlais R.L., Schubert C., Petrounia I.P., Chaikin M.A., Manthey C.L., and Player M.R. Bioorg. Med. Chem. Lett. 18 (2008) 2355
19. Brown D.S., Belfield A.J., Brown G.R., Campbell D., Foubister A., Masters D.J., Pike K.G., Snelson W.L., and Wells S.L. Bioorg. Med. Chem. Lett. 14 (2004) 5383
20. Deak H.L., Newcomb J.R., Nunes J.J., Boucher C., Cheng A.C., DiMauro E.F., Epstein L.F., Gallant P., Hodous B.L., Huang X., Lee J.H., Patel V.F., Schneider S., Turci S.M., and Zhu X. Bioorg. Med. Chem. Lett. 18 (2008) 1172
21. Chen N., Burli R.W., Neira S., Hungate R., Zhang D., Yu V., Nguyen Y., Tudor Y., Plant M., Flynn S., Meagher K.L., Lee M.R., Zhang X., Itano A., Schrag M., Xu Y., Ng G.Y., and Hu E. Bioorg. Med. Chem. Lett. 18 (2008) 4137
22. For enzyme assay procedures see: Almeida, L.; Aquila, B.; Cook, D.; Cowen, S.; Dakin, L.; Ezhuthachan, J.; Ioannidis, S.; Lee, S.; Lyne, P.; Pontz, T.; Scott, D.; Su, M.; Zheng, X. WO 06067445 A2 20060629; Chem. Abstr. 2006, 145, 124467. Cell proliferation assay: 3T3 cells engineered to express human full length CSF-1R were seeded into 96-well microplates (Costar, Corning, Lowell, MA) in phenol red-free DMEM (Invitrogen, Carlsbad, CA) containing 0.05% bovine serum albumin. After overnight incubation, cells were treated with DMEM containing DMSO (100% inhibition) or DMEM containing 80 ng/ml M-CSF (R&D Systems, Minneapolis, MN) and insulin, transferrin and selenium (Biowhitaker, Walkersvilee, MD) in the presence of DMSO (0% inhibition) or multiple concentrations of compound. Plates were then returned to the incubator for 72 h and growth determined using the CellTiter 96 Aqueous One Cell Proliferation Assay (Promega, Madison, WI). Quantification of signal was determined using a SpectraMax plate reader (Molecular Devices, Sunnyvale, CA).
23. Lyne, P. D.; Aquila, B. M.; Cook, D. J.; Dakin, L. A.; Ezhuthachan, J.; Ioannidis, S.; Pontz, T.; Su, M.; Ye, Q.; Zheng, X.; Block, M. H.; Cowen, S.; Deegan, T. L.; Lee, J.; Scott, D. A.; Custeau, D.; Drew, L.; Poondru, S.; Shen, M.; Wu, A. Unpublished results.
24. Aquila, B.; Cook, D.; Dakin, L.; Ioannidis, S.; Lyne, P.; Scott, D.; Zheng, X. WO 07071955 A1 20070628; Chem. Abstr. 2007, 147, 118215.
25. Thiel W. J. Prakt. Chem. 332 (1990) 845
26. Davy H.J. Chem. Soc. Chem. Commun. 8 (1982) 457
27. KinaseProfiler Department, Millipore UK Limited, Gemini Crescent, Dundee Technology Park, Dundee DD2 1SW, UK.